A perspective on hyperlipidemia: Concepts of management in the prevention of coronary artery disease

American Journal of Medicine

Volumn 105, Issue 1 A, 1998, Pages 69S-74S

  Amsterdam, Ezra A ^a,b   Deedwania, Prakash C ^c  

^a Dept Ophthalmol Univ C   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; COLESTIPOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; DIET THERAPY; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

EID: 0032490703     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00215-0     Document Type: Conference Paper

References (41)

1. Deedwania P.C. Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. Med Clin North Am. 79:1995;973-998.
2. Brown M.S., Goldstein J.L. Heart attacks gone with the century? (Editorial) Science. 272:1996;629.
3. Pearson T.A., McBride P.E., Miller N.H., Smith S.C. Task Force 8 organization of preventive cardiology service, from the 27th Bethesda Conference . J Am Coll Cardiol. 27:1996;1039-1047.
4. Heart and Stroke Facts: 1997 Statistical Supplement. Dallas, TX: American Heart Association; 1997.
5. Fact Book Fiscal Year 1997. Bethesda, MD: National Heart, Lung, and Blood Institute; 1997.
6. Pekkanen J., Linn S., Heiss G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 322:1990;1700-1707.
7. Amsterdam E.A., Hyson D., Kappagoda C.T. Nonpharmacologic therapy for coronary artery atherosclerosis results of primary and secondary prevention trials . Am Heart J. 128:1994;1344-1352.
8. Lewis B., Watts G.F. Paradise regained insights into coronary heart disease prevention from recent clinical trials and basic research . J Royal Coll Phys. 31:1997;263-275.
9. Merz C.N.B., Rozanski A., Forrester J.S. The secondary prevention of coronary artery disease. Am J Med. 102:1997;572-581.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
11. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
12. Stone N.J. The clinical and economic significance of atherosclerosis. Am J Med. 101:(suppl):1996;6S-9S.
13. Faxon D.P. Introduction and historical background. Faxon D.P. Practical Angioplasty. 1994;1-5 Raven Press, New York.
14. Takaro T., Pifarre R., Fish R. Left main coronary artery disease. Prog Cardiovasc Dis. 28:1985;229-234.
15. Passamani E., Davis K.B., Gillespie M.J., et al. A randomized trial of coronary artery bypass surgery Survival of patients with a low ejection fraction . N Engl J Med. 312:1985;1665-1671.
16. Forrester J.S., Shah P.K. Lipid lowering versus revascularization an idea whose time (for testing) has come . Circulation. 96:1997;1360-1362.
17. Pilote L., Califf R.M., Sapp S., et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med. 333:1995;565-572.
18. Pilote L., Miller D.P., Califf R.M., et al. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med. 335:1996;1198-1205.
19. Reeder G.S. Identification and management of the low-risk patient after myocardial infarction. ACC Current J Rev. 6:1997;27-31.
20. Deedwania P.C., Amsterdam E.A., Vagelos R.H., et al. Evidence-based, cost-effective risk stratification and management after myocardial infarction. Arch Intern Med. 157:1997;273-280.
21. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
22. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
23. Waters D. Plaque stabilization a mechanism for the beneficial effect of lipid-lowering therapies in angiography studies . Progress in Cardiovas Dis. 37:1994;107-120.
24. Nakagomi A., Celermajer D.S., Lumley T., Freedman S.B. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. Am J Cardiol. 78:1996;516-519.
25. Superko H.R., Krauss R.M. Coronary artery disease regression convincing evidence for the benefit of aggressive lipoprotein management . Circulation. 90:1994;1056-1069.
26. Brown B.G., Zhao X.-Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression new insights into prevention of plaque disruption and clinical events in coronary disease . Circulation. 87:1993;1781-1791.
27. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
28. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
29. Ashraf T., Hay J.W., Pitt B., et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 78:1996;409-414.
30. Johannesson M., Jönsson B., Kjekshus J., et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 336:1997;332-336.
31. Eichstädt H.W., Eskotter H., Hoffman I., et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol. 76:(suppl):1995;122A-125A.
32. van Boven A.J., Jukema J.W., Zwinderman A.H., et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 94:1996;1503-1505.
33. Andrews T.C., Raby K., Barry J., et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.
34. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
35. Crouse J.R. III, Byington R.P., Hoen H.M., Furberg C.D. Reductase inhibitor monotherapy and stroke prevention. Ann Intern Med. 157:1997;1305-1310.
36. Amsterdam E.A. Epidemiologic studies of diet and drug therapy to reach target LDL-C levels. Am J Managed Care. 2:(suppl I):1996;25S-30S.
37. Swan H.J.C., Gersh B.J., Graboys T.B., Ullyot D.J. Task Force 7 evaluation and management of risk factors for the individual patient (case management), from the 27th Bethesda Conference . J Am Coll Cardiol. 27:1996;1030-1039.
38. Smith S.C. Jr, Blair S.N., Criqui M.H., et al. Preventing heart attack and death in patients with coronary disease. Circulation. 92:1995;2-4.
39. Grundy S.M., Balady G.J., Criqui M.H., et al. Guide to primary prevention of cardiovascular diseases a statement for healthcare professionals from the Task Force on Risk Reduction . Circulation. 95:1997;2329-2331.
40. Fuster V, Pearson TA, co-chairs. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996;27:957-1047.
41. Grundy S.M., Balady G.J., Criqui M.H., et al. When to start cholesterol-lowering therapy in patients with coronary heart disease a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction . Circulation. 95:1997;1683-1685.